Skip to main content
Alteogen Inc. logo

Alteogen Inc. — Investor Relations & Filings

Ticker · 196170 ISIN · KR7196170005 KO Professional, scientific and technical activities
Open in API
Filings indexed 293 across all filing types
Latest filing 2021-08-23 Report Publication Anno…
Country KR South Korea
Listing KO 196170

About Alteogen Inc.

http://www.alteogen.com/

Alteogen Inc. is a biopharmaceutical company focused on the development and commercialization of next-generation biologics. The company's core activities are centered on its proprietary platform technologies. These include Hybrozyme™, a novel recombinant human hyaluronidase (ALT-B4) technology that enables the conversion of intravenous (IV) therapies to subcutaneous (SC) formulations, enhancing patient convenience. Additionally, Alteogen develops long-acting biobetters utilizing its NexP™ fusion technology, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars. The company's pipeline is aimed at creating therapies with enhanced efficacy and delivery methods for serious diseases.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an official announcement regarding an upcoming Investor Relations (IR) conference/presentation event. It details the date, location, purpose, and agenda for the '2021 KOSDAQ IR Conference'. Since it is an announcement of an event rather than the presentation slides themselves or a full financial report, and it fits the criteria for a regulatory announcement of an IR activity, it is classified as a Regulatory Filing (RNS).
2021-08-23 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'Alteogen' covering the period from January 1, 2021, to June 30, 2021. It contains detailed corporate information, history, capital changes, and shareholding structures, which are characteristic of a comprehensive interim financial report. It is not an announcement or a certification, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-17 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) which is the Korean equivalent of an Annual Report (10-K). It contains detailed financial information, company history, management structure, and governance details for the fiscal year 2020. Although it is labeled as a '정정신고' (Correction Report), it is a comprehensive filing that includes the full annual report content, not just a brief announcement or certification. Therefore, it is classified as an Annual Report (10-K). FY 2020
2021-08-10 Korean
기타경영사항(자율공시)(아일리아 바이오시밀러 ALT-L9 국내 임상 1상 시험 결과)
Regulatory Filings Classification · 95% confidence The document is a formal regulatory disclosure filed by Alteogen regarding the results of a Phase 1 clinical trial for its biosimilar product, ALT-L9. It follows the standard format of a 'voluntary disclosure' (자율공시) common in Korean stock exchange filings. Since it details specific clinical trial outcomes, safety data, and future development plans, it falls under the category of general regulatory announcements that do not fit into specific financial reporting categories like 10-K or Earnings Releases. Therefore, it is classified as a Regulatory Filing (RNS).
2021-08-04 Korean
투자판단관련주요경영사항(HER2 양성 유방암 대상자 중 표준 치료에 실패한 전이를 가진 진행성 또는 재발성 환자에게 ALT-P7을 주사제로 투여하여 안전성, 약동학, 항암효과를 평가하는 국내 임상1상 시험결과)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure filed by Alteogen regarding the results of a Phase 1 clinical trial for its drug candidate ALT-P7. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KRX), which is used to report material events such as clinical trial outcomes. Since it details specific trial results, safety data, and efficacy metrics rather than just announcing a report's availability, it falls under the category of regulatory filings for material corporate events.
2021-08-03 Korean
기타경영사항(특허권취득)(자율공시)(FOLR1에 특이적으로 결합하는 항체 및 그의 용도)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from Alteogen regarding the acquisition of a patent (FOLR1-binding antibody). It follows the standard format for a voluntary disclosure of material management information in the Korean market. Since it does not fit into specific categories like financial reports, M&A, or shareholder meetings, it falls under the general regulatory filing category.
2021-07-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.